VAQTA is indicated for the prevention of disease caused by hepatitis A
virus (HAV) in persons 12 months of age and older.
The primary dose should
be given at least 2 weeks prior to expected exposure to HAV.
CALL US
0151 482 2850
£71.34
Availability: In stock
£71.34
VAQTA is indicated for the prevention of disease caused by hepatitis A
virus (HAV) in persons 12 months of age and older.
The primary dose should
be given at least 2 weeks prior to expected exposure to HAV.